Thalidomide and rituximab in Waldenstrom macroglobulinemia

Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended therapy consisted of daily thalidomide (200 mg fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Treon, Steven P., Soumerai, Jacob D., Branagan, Andrew R., Hunter, Zachary R., Patterson, Christopher J., Ioakimidis, Leukothea, Briccetti, Frederick M., Pasmantier, Mark, Zimbler, Harvey, Cooper, Robert B., Moore, Maria, Hill, John, Rauch, Alan, Garbo, Lawrence, Chu, Luis, Chua, Cynthia, Nantel, Stephen H., Lovett, David R., Boedeker, Hans, Sonneborn, Henry, Howard, John, Musto, Paul, Ciccarelli, Bryan T., Hatjiharissi, Evdoxia, Anderson, Kenneth C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2008
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2597120/
https://ncbi.nlm.nih.gov/pubmed/18713945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-04-150854
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars